After the treatment of ARNIPL to 3D cancer spheroids, ARV-825 induced the BRD4 depletion-associated down-regulation of c-Myc, and nintedanib inhibited the transforming growth factor beta 1 (TGF-β1), resulting in synergistic antitumor efficacy. Here, MYC is linked to cancer.